BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24376816)

  • 1. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
    Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
    PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of small molecule human papillomavirus E6 inhibitors.
    Malecka KA; Fera D; Schultz DC; Hodawadekar S; Reichman M; Donover PS; Murphy ME; Marmorstein R
    ACS Chem Biol; 2014 Jul; 9(7):1603-12. PubMed ID: 24854633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
    Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
    Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
    Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
    Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
    Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein.
    Ricci-López J; Vidal-Limon A; Zunñiga M; Jimènez VA; Alderete JB; Brizuela CA; Aguila S
    PLoS One; 2019; 14(3):e0213028. PubMed ID: 30875378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
    Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
    Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MicroRNAs That Stabilize p53 in Human Papillomavirus-Positive Cancer Cells.
    Martínez-Noël G; Szajner P; Kramer RE; Boyland KA; Sheikh A; Smith JA; Howley PM
    J Virol; 2022 Feb; 96(4):e0186521. PubMed ID: 34878887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP binding.
    Cho Y; Cho C; Joung O; Lee K; Park S; Yoon D
    Antiviral Res; 2000 Sep; 47(3):199-206. PubMed ID: 10974372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
    Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
    J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
    Drews CM; Case S; Vande Pol SB
    PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
    Drews CM; Brimer N; Vande Pol SB
    PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers.
    Zhou Y; Wei Y; Zhu J; Wang Q; Bao L; Ma Y; Chen Y; Feng D; Zhang A; Sun J; Nallar SC; Shen K; Kalvakolanu DV; Xiao W; Ling B
    PLoS One; 2011; 6(7):e22065. PubMed ID: 21765936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
    Thatte J; Banks L
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.
    Brimer N; Drews CM; Vande Pol SB
    PLoS Pathog; 2017 Dec; 13(12):e1006781. PubMed ID: 29281732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
    Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
    J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
    Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
    J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.
    Tomaić V; Pim D; Banks L
    Virology; 2009 Oct; 393(1):7-10. PubMed ID: 19700180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
    Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
    PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.
    Wang H; Mo P; Ren S; Yan C
    J Biol Chem; 2010 Apr; 285(17):13201-10. PubMed ID: 20167600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.